The association between Lambert--Eaton myasthenic syndrome and small cell lung carcinoma

Briggs, Sarah E. W.; Gozzard, Paul; Talbot, Denis C.
May 2013
ImmunoTargets & Therapy;May2013, Vol. 2, p31
Academic Journal
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder mediated by autoantibodies to voltage-gated calcium channels. The disorder is diagnosed clinically on the basis of a triad of symptoms (proximal muscle weakness, hyporeflexia, and autonomic disturbance), supported by electrophysiological findings and the presence of autoantibodies. Between 40% and 62% of patients diagnosed with LEMS are found to have small-cell lung cancer (SCLC), almost all of whom develop neurological symptoms before their cancer is diagnosed. Prompt identification of LEMS and appropriate screening for SCLC is key to improving the outcome of both conditions. Here we review the pathophysiology and clinical management of LEMS, focusing particularly on the relationship with SCLC.


Related Articles

  • Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy. Gilhus, Nils Erik // Autoimmune Diseases (2090-0422);2011, p1 

    Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare disease with a well-characterized pathogenesis. In 50% of the patients, LEMS is a paraneoplastic manifestation and caused by a small cell lung carcinoma (SCLC). Both LEMS patients with SCLC and those without this tumour have in 85% of cases...

  • Lambert-Eaton Myasthenic Syndrome presenting with a 'dropped head syndrome' and associated with antibodies against N-type calcium channels. Rácz, Attila; Giede-Jeppe, Antje; Schramm, Axel; Schwab, Stefan; Maihöfner, Christian // Neurological Sciences;Jul2013, Vol. 34 Issue 7, p1253 

    No abstract available.

  • Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report. KEJIAN ZHANG; WEI LIU; YANG LI; KEWEI ZHANG; XINLIANG GAO; JING WANG // Experimental & Therapeutic Medicine;2015, Vol. 10 Issue 1, p117 

    Lambert-Eaton myasthenic syndrome (LEMS) is typically characterized as a paraneoplastic syndrome associated with small cell lung carcinoma. The presence of LEMS in association with other neuroendocrine lung tumors, including carcinoids or large cell lung carcinoma, is highly unusual. The present...

  • Neuromuskul�re Irrwege. Kolev, M.; Oppliger, S.; Jung, S.; Steiner, S. // Praxis (16618157);1/16/2013, Vol. 102 Issue 2, p111 

    We report the case of a 54-year old man with slowly progressive symmetrical weakness of the proximal legs and atactic gait. The diagnostic work-up is reviewed. It revealed the diagnosis of a Lambert-Eaton myasthenic syndrome (LEMS) and SIADH caused by a small cell lung cancer (SCLC).

  • Paraneoplastic neurologic disorders in small cell lung carcinoma. O'Sullivan, Eoin // Current Medical Literature: Ophthalmology;2015, Vol. 25 Issue 3, p94 

    The article discusses a 2015 study by P. Gozzard et al and published in the journal "Neurology" that reveals the prevalence of paraneoplastic neurologic disorders in patients with small cell lung carcinoma. Topics include Lambert-Eaton Myasthenic Syndrome, voltage-gated calcium channel...

  • Lambert-Eaton myasthenic syndrome in patients with small cell lung cancer: Report of five cases. Yueqiao Hao; Jinmeng Hu; Yajun Zhang; Weichao Liu; Shanshan Lu; Min Zhang // Journal of Cancer Research & Therapeutics;2015 Sepcial Issue1, Vol. 11, pC95 

    Objective: To further evaluate the clinical characteristics of small cell lung cancer (SCLC) with Lambert-Eaton syndrome. Methods: We reviewed the patient database of our hospital from 2001 to 2013 to evaluate and analyze the patients of SCLC with Lambert-Eaton syndrome. The clinical...

  • Long-Term Follow-Up in Infantile-Onset Lambert-Eaton Myasthenic Syndrome. Portaro, S.; Parisi, D.; Polizzi, A.; Ruggieri, M.; Andreetta, F.; Bernasconi, P.; Toscano, A.; Rodolico, C. // Journal of Child Neurology;Sep2014, Vol. 29 Issue 9, pNP58 

    Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung...

  • Successful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report. JAE-WON HYUN; SU-HYUN KIM; IN HYE JEONG; HEUNG TAE KIM; HO JIN KIM // Oncology Letters;Mar2016, Vol. 11 Issue 3, p1933 

    Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the neuromuscular junction that is characterized by muscle weakness. LEMS is usually associated with cancer, most commonly small cell lung cancer (SCLC). The potassium-channel blocker 3,4-diaminopyridine (3,4-DAP), has been...

  • Myasthenia Gravis. Aarli, Johan A.; Gilhus, Nils Erik; Lisak, Robert P.; Mantegazza, Renato; Suzuki, Shigeaki // Autoimmune Diseases (2090-0422);2011, p1 

    An introduction to the journal is presented in which the editor discusses various reports within the issue on topics related to Myasthenia gravis (MG) including Lambert-Eaton Myasthenic Syndrome (LEMS), role of B-cell activating factor (BAFF) and Epstein-Barr virus (EBV) in MG's pathogenesis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics